Saol Therapeutics Resubmits NDA for SL1009 (DCA) in Pyruvate Dehydrogenase Complex Deficiency Following FDA Alignment
核心洞察
Saol Therapeutics has resubmitted its NDA for SL1009 (sodium dichloroacetate) (搜索) to the FDA for treating pyruvate dehydrogenase complex deficiency (搜索), a rare mitochondrial disease with no approved therapies.
The resubmission follows a Complete Response Letter in August 2025 and incorporates additional survival analyses requested by the FDA, without requiring a new clinical trial.
SL1009 has received Priority Review, Orphan Drug Designation, and Rare Pediatric Disease Designation, with Saol anticipating a Priority Review Voucher upon approval.
Saol Therapeutics, a privately held clinical-stage pharmaceutical company, announced on July 7, 2026 the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex deficiency (搜索) (PDCD). PDCD is a rare, life-threatening mitochondrial disease for which no FDA-approved therapies currently exist.
The resubmission follows a Complete Response Letter (CRL) issued by the FDA in August 2025. Notably, the CRL did not identify concerns related to safety or manufacturing, but requested additional evidence to support approval. In response, Saol conducted further analyses of existing data, including functional outcomes, survival, mechanistic evidence, and long-term safety data.
Regulatory Pathway and FDA Engagement
Following the CRL, Saol held a Type A meeting in December and a Type C meeting in March, during which the FDA provided guidance recommending additional survival analyses to support the application. This guidance enabled Saol to proceed directly to resubmission without conducting an additional trial.
"We are encouraged by the clarity and alignment achieved with the FDA during our recent interactions," said Dave Penake, chief executive officer of Saol Therapeutics. "This resubmission reflects the totality of evidence supporting SL1009. We are committed to continuing to work collaboratively with the Agency and are encouraged by the FDA's demonstrated willingness to apply regulatory flexibility."
Penake further acknowledged the role of the patient community, stating, "We are grateful for the continued engagement of the PDCD community and experts, whose efforts have helped communicate the impact of this disease on affected individuals and families."
Clinical Evidence Supporting the Application
SL1009 has been studied across multiple clinical trials, including two Phase 3 studies and long-term open-label extension data, supporting a well-characterized safety profile. While the primary endpoint of the first Phase 3 trial was not met during the blinded phase, patients receiving long-term treatment demonstrated significant improvements in motor function and reductions in plasma lactate. A second study comparing DCA-treated patients with a matched natural history cohort showed improved survival, and these analyses have been expanded in the resubmission.
Saol believes the totality of evidence supports the potential for meaningful clinical benefit in patients with PDCD.
Disease Background and Unmet Need
PDCD is caused by defects in the pyruvate dehydrogenase complex, leading to impaired energy production, chronic lactic acidosis, severe neurological impairment, and high mortality in early-onset disease. The condition can cause chronic energy deficit leading to lactic acidosis, profound developmental problems, and early childhood death. Current treatment is limited to ketogenic diets, nutritional supplementation, and supportive care.
Companion Diagnostic and Regulatory Designations
SL1009 is an investigational oral DCA solution intended for use with a proprietary dose-determining genetic test. Saol, in collaboration with Medosome Biotec (搜索), filed a Humanitarian Device Exemption application for this companion diagnostic, which identifies GSTZ1 (搜索) genotypes to guide individualized dosing and reduce the risk of peripheral neuropathy.
SL1009 has received Priority Review, Orphan Drug Designation, and Rare Pediatric Disease Designation from the FDA. Saol anticipates receiving a Priority Review Voucher under the Rare Pediatric Disease Statute upon approval. The FDA will assign a new action (PDUFA) date upon acceptance of the file.
If approved, SL1009 would become the first FDA-approved pharmacological treatment for PDCD, providing a therapeutic option for a disease currently managed only with supportive care. Access to the therapy has continued through an ongoing open-label extension study and expanded access program.